Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Crossref DOI link: https://doi.org/10.1186/s40425-016-0158-5
Published Online: 2016-09-20
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rehman, Hasan
Silk, Ann W.
Kane, Michael P.
Kaufman, Howard L.
Funding for this research was provided by:
National Cancer Institute (UM1 CA 186716-01)